Researcher organizing samples for a receptor assay

Growth Axis · Laboratory protocol

CJC-1295 No DAC

GHRH-receptor agonist based on GHRH(1-29), supplied without the drug-affinity complex. The no-DAC form is the short-acting analog.

For laboratory research use only. Material is supplied as a research reference standard and is not approved by Health Canada. Protocols below are compiled from published literature and supplier documentation; they are reference information, not medical advice. Anyone with a health condition or on medication should speak to a physician first.

Before you begin

• Lot-matched certificate and laboratory notebook
• Calibrated pipettes, low-binding tubes and suitable PPE
• Validated solvent, assay reagents and model-specific SOP
• Appropriate positive, negative and vehicle controls

Workflow

1Review the lot-matched COA and record identity, purity, batch number and received condition.
2Let the sealed vial equilibrate to room temperature before opening to limit condensation.
3Calculate the target stock concentration with C = mass / volume. Use only a solvent validated for the planned assay.
4Add solvent slowly down the vial wall, mix gently and avoid vortexing unless the validated method permits it.
5Prepare a log-spaced pilot concentration series; determine the usable range empirically instead of assuming a biological dose.
6Run the defined controls and technical replicates alongside every plate or experiment.
7Record preparation time, temperature, equipment, deviations and raw-data file locations.

Assay design

A GHRH-R reporter or pituitary secretion model. Where the research question is synergy with a GHS-R1a ligand, both arms need their own single-agent curves before any combination point is interpretable.

Required controls

Vehicle-only negative control
Receptor-null or antagonist condition
Validated reference ligand
Untreated viability control

Reported protocol

Standard: 100 mcg per injection, paired 1:1 with ipamorelin in the blend protocol
Frequency: 1 to 3 times daily (morning, post-workout, pre-bedtime)
Fasting requirement: Administer on an empty stomach: no food 2 h before, 30 min after
Route: Subcutaneous

Diluent

Sterile bacteriostatic water (0.9% benzyl alcohol) for multi-withdrawal stock, or sterile water for injection where a preservative-free stock is required by the assay.

Compound-specific: Confirm you are working with the no-DAC analog before comparing against any published result. A large part of the CJC-1295 literature uses the DAC-modified molecule and the kinetics are not comparable.

Reconstitution concentrations

Solvent volume sets the stock concentration for this 10 mg vial. Lower volume gives a more concentrated stock and smaller working aliquots; higher volume gives a more dilute stock that is easier to measure accurately.

Stock concentration by solvent volume for a 10 mg vial
Solvent added	Stock concentration	Per 0.1 mL	Per unit (U-100)
1 mL	10 mg/mL	1 mg	100 mcg
2 mL	5 mg/mL	500 mcg	50 mcg
3 mL	3.33 mg/mL	333.33 mcg	33.33 mcg

Working range

GHRH-R reporter work typically runs a log-spaced nanomolar series.

Stability

Lyophilized: Stable sealed and dry at the certificate temperature.
In solution: Establish empirically. Short-acting analogs are usually prepared fresh for the run.

Handling notes

Label every aliquot explicitly as no-DAC. Mislabelling against DAC material invalidates the run.
Prepare working dilutions close to the time of use.
For combination work, single-agent curves come first, always.

Documentation checklist

Record lot and COA, mass balance, solvent and concentration, preparation timestamp, storage history, plate map, replicate plan, instrument settings, exclusions and deviations. Preserve raw data and analysis code with the experiment record.